Abstract
Overview
Introduction
Stroke is one of the top three leading causes of death worldwide and an area
of high unmet needs. TPA is limited to a low number of ischemic stroke
patients due to a short therapeutic time window, but it is still the best
therapy available. TPA is responsible for major changes and advances in the
way stroke patients are cared for, which is expected to evolve further.
Scope
- Review of the available epidemiology data to assess the patient population
of acute stroke.
- Outline of the existing therapy options and the current prescribing trends.
- Assessment of treatment outcomes and unmet needs associated with the
outcomes.
- Evaluation of the developmental agents in late stage clinical trials.
Report Highlights
The incidence of stroke has been slowly declining over the last 50 years, as
well as mortality from stroke. However, stroke continues to be a major public
health concern, being the third leading cause of death in the US after heart
disease and cancer, and the leading neurologic cause of long-term disability.
The presently available tPA, while very efficacious, is to be used in acute
ischemic stroke patients within the 3 hour time window since the onset of
stroke symptoms. In order for more patients to be eligible for the treatment
with the tPA, there should be more focus on significant infrastructure
improvements in all of the major markets.
There has been a lack of progress in acute stroke drug development. Over the
last 20 years huge efforts have been expended in developing neuroprotectants.
Over 100 reached clinical evaluation but none has clearly demonstrated
efficacy. The agents currently in late stage development do not offer much
hope in replacing or contributing to tPA therapy.
Reasons to Purchase
- target physicians more effectively, through an understanding of
prescribing behavior and its influences.
- validate new product forecasting based on diagnosis and treatment rates,
and the likely rate of uptake for new products.
- understand clinical trial requirements to prepare more effective NDAs.
| 
View Cart
